SMAD4 is a critical cofactor in signal transduction pathways activated in response to transforming growth factor-beta (TGF-b)-related ligands, regulating cell growth and differentiation. The roles played by SMAD4 inactivation in tumours highlighted it as a tumoursuppressor gene. However, restoration of the TGF-b antiproliferative pathway following SMAD4 gene transfer in null-tumour cell lines is controversial. Herein, we report the inhibitory effects of SMAD4 on pancreatic tumour invasion and angiogenesis. Adenoviral transfer of this gene in a panel of SMAD4 homozygous-deleted human pancreatic tumour cell lines restored SMAD4 protein expression and function. Although it did not affect proliferation significantly in vitro, SMAD4 inhibited in vivo tumour growth in immunodeficient mice. In this xenograft setting, differential suppression of tumour growth in vivo was mediated, at least in part, through downregulation of vascular endothelial growth factor and expression of gelatinases. We documented the reduced invasion and angiogenesis histologically and by intravital microscopy, and gained mechanistic insight at the messenger and protein level. Finally, we found a negative reciprocal regulation between SMAD4 and ETS-1. ETS-1 is considered a marker for tumour invasion. Upon SMAD4 deletion, we detected high expression levels of ETS-1 in pancreatic tumour cells, suggesting the shift of the pancreatic tumour toward an invasive phenotype.
Introduction
SMAD proteins are distributed in the cytoplasm and nucleus. The SMAD4 (Ramachandra et al., 2002) gene is located on chromosome 18q21, a putative location for other tumour-suppressor genes (TSGs, Lefter et al., 2002) . It is inactivated in half of pancreatic carcinomas (Calonge and Massague, 1999) , and as we reported previously, SMAD4 inactivation is associated with a poor prognosis (Yatsuoka et al., 2000) . Frequent loss of 18q is observed at the early stage of pancreatic tumours (Fukushige et al., 1998) , in contrast to SMAD4 inactivation, which seems to occur at a later stage (Inoue et al., 2001) . SMAD4 interacts with specific SMAD proteins to interfere with the cell cycle, and it plays a pivotal role in the embryonic development, by distinct transforming growth factor-beta (TGF-b) signalling pathways (Lagna et al., 1996) . More specifically, these pathways function by SMAD4 heterodimerization with activated SMAD2 or its isoform SMAD3 upon TGF-b receptor type II (via TGF-bI) or activin phosphorylation, whereas SMAD1/5/8 act downstream of the bone morphogenic proteins and associate with SMAD4. The resulting complexes translocate into the nucleus where they regulate transcription of certain genes (Lagna et al., 1996) . In adenocarcinoma, malignant transformation of epithelial cells is the result of a sequence of oncogene and TSG mutations (Takaku et al., 1998) . By stable transfer of chromosome 18, we have previously demonstrated the existence of an additional TSG, other than SMAD4, responsible for the pathogenesis in the early stage of pancreatic ductal carcinogenesis (Lefter et al., 2002) . In addition, an interesting finding constituted the fact that the highly frequent activating mutation of KRAS occurs early in gastrointestinal cancer and was reported to disrupt jointly the TGF-b antiproliferative responses incurred by SMAD4 silencing, a later event (Wilentz et al., 2000) , through the inhibition of the SMAD2/3 function (Calonge and Massague, 1999) . The concomitant presence of these two mutations has been offered as an explanation for the fact that SMAD4 restoration in some tumour cells did not rescue the TGF-b antiproliferative and gene responses (Calonge and Massague, 1999) . The simultaneous presence of two distinct TGF-b inhibitory hits also suggested that SMAD4 has pleiotropic effects, resulting in an alternative role in vivo, which accounts for the suppression of tumour growth. One such effect was reported recently, implicating SMAD4 for the first time as an inhibitor of pancreatic tumour angiogenesis, and identifying thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF) as relevant tumour targets (Schwarte-Waldhoff et al., 2000) .
Restoration of TGF-b responsiveness in SMAD4-null cells resulted in different outcomes depending on the tumour type. In breast and colon carcinoma, SMAD4 inhibited cell proliferation and induced anoikis, while in pancreatic carcinoma the response was angiogenesis inhibition (Schwarte-Waldhoff et al., 2000; Fink et al., 2001; Ramachandra et al., 2002) . Herein, we investigated both the physiology and the molecular mechanism associated with SMAD4 inactivation in variety of pancreatic tumour cell lines to better understand its role in the progression of this disease. We assessed the growth and the angiogenic response of human pancreatic tumour in severe-combined immunodeficient (SCID) mice, as well as the expression of various factors associated with invasion and local angiogenesis balance in these tumours and in primary human tumours. Matrix metalloproteinases (MMPs), in particular the gelatinases, have been found to be involved in tumour growth, invasion, angiogenesis, and promotion (Nelson et al., 2000) . In addition, recent evidence suggests that ETS-1 transcription factor is a key regulator of vasculogenesis and angiogenesis. It is expressed in lymphocytes in adult, but also in mesoderm lineage including endothelial cells (ECs) during embryogenesis. Moreover, it was reported that its induction is a mutual phenomenon in response to proangiogenic factors, regulating the expression of VEGF receptors Flt-1 (Valter et al., 1999) and Flk-1 (through interaction with HIF-2a (Elvert et al., 2003) as well as the local proteolytic balance and migration of cells (Iwasaka et al., 1996; Kita et al., 2001) . Over the last several years, ETS-1 expression in a variety of carcinoma cells, including pancreatic, ovarian, and colorectal has been documented (Ito et al., 1998; Kita et al., 2001; Nakayama et al., 2001) and it has consistently correlated with tumour invasion and poor prognosis. Among the MMPs regulated by ETS-1, MMP-2, and MMP-9 appear to be the major players downstream of this signalling factor (Nishikawa et al., 2000; Behrens et al., 2001; Reisdorff et al., 2002) .
Results

SMAD4 overexpression in pancreatic cell lines
The activity of Ad/SMAD4 virus was confirmed using PK-1 (SMAD4-null) and MiaPaCa2 (SMAD4-wildtype) cells, respectively (Sun et al., 2001) . SMAD4 RNA expression was confirmed in MiaPaCa2 cells but not in noninfected or control virus-infected PK-1 cells. The transfer was efficient and we assessed a dosedependent overexpression in all cells at 36 h after infection with various multiplicity of injection (MOI) of (Ad/SMAD4 (Figure 1a, b) . To examine the DNAbinding activity of ectopically expressed SMAD4 we performed electrophoretic mobility shift assays (EMSAs) using a 32 P-labelled double-stranded SBE probe from the p21 WAF1 gene promoter region, as described (Peng et al., 2002) . SMAD4-specific DNA-binding activities were absent in either PK-1 wild-type or control cells (Figure 1c, lanes 7 and 8) . Furthermore, SMAD4-specific DNA-binding activities appeared markedly induced in the PK-1/SMAD4 infected (lane 9), at levels comparable with those exhibited by MiaPaCa2, HPDEC-6, or WI38 cells (lanes 1-3, 13, 14) . The cold competition showed that the SMAD4-DNA-binding activity was specific (lanes 5 and 11), and supershift assays showed that the DNA binding consisted of SMAD4 (lanes 4 and 10). Moreover, a 32 P-labeled mutant SBE probe was unable to exhibit any binding activity (lanes 6 and 12). Taken together, these data show that re-expression of functional SMAD4 can be efficiently obtained via adenoviral-mediated gene transfer.
SMAD4 effect on in vitro tumour cell growth
The use of the adenoviral vector conferred a dosedependent protein expression (Figures 1a, b and 4a) , with a high efficiency of the gene transfer (over 90% of the cells were b-galactosidase positive, after staining of Ad/LacZ-infected cells, not shown). The 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide Figure 1 Expression of SMAD4 mRNA and DNA-binding activity after adenoviral transfection of SMAD4. PK-1 (a) and MiaPaCa2 (b) were infected using Ad/SMAD4 at the MOI specified (c -control LacZ) and 15 mg of the total RNA extracted subsequently was subjected to Northern blot analysis. The levels of b-actin were used to confirm equal loading for each lane. Specific SMAD4 DNA-binding activity (c) was determined by an EMSA using a wild-type or mutant SBE (WT or MT-SBE) (MTT) assays showed no significant cytotoxic effects upon SMAD4 restoration or overexpression in any of the five human pancreatic adenocarcinoma cell lines tested (Figure 2a) . Thus, the transfer of SMAD4 did not rescue the TGF-b antiproliferative effects in vitro.
Effect of SMAD4 on in vivo tumour growth
In sharp contrast to the in vitro results, in vivo growth after subcutaneous (s.c.) inoculation of SMAD4-trasfected cells was suppressed as compared to parental cells or LacZ transfectants (Figure 2b-d) . In this tumour xenografts model, there was a significant delay in the growth of tumours in which SMAD4 expression was restored up to 1 month. After 1 month, the transduced SMAD4 expression in tumour cells was reduced due to the transient nature of the adenoviral transfer, and tumours relapsed.
More significantly, using dorsal skin chamber and intravital microscopy, it was demonstrated and visualized directly that implantation of SMAD4 tumourtransfected cells failed to promote tumour growth and an angiogenic phenotype encountered in the wild-type or LacZ-transfected cells (supplemental Figure 1) . At 3 weeks after implantation of PK-1 cells transfected with SMAD4 on the skin, although the implanted cells formed microscopic tumours detected histologically (Figure 3a) , they failed to invade the adjacent layers and induce neovascularization. In contrast, well-vascularized growing tumours could be observed in the skin chambers that received wild-type or LacZ-transfected PK-1 cells (Figure 3b , c).
Immunostaining for ECs and gelatinases
Delayed tumour growth correlated with decreased vascularization in the SMAD4-transfected tumour tissue, as found by immunostaining for tumour vessels using CD31. Furthermore, immunostaining for the gelatinases (MMP-2 and MMP-9) indicated high levels Figure 2 SMAD4 expression induces an inhibitory effect in vivo on xenografted tumours, but not on the in vitro tumour cell proliferation. SMAD4 restoration through efficient adenoviral transfection failed to restore the TGF-b-induced growth inhibition of pancreatic adenocarcinoma cells, as no significant cytotoxic effect was found using the MTT assay, regardless of the SMAD4 status (a). In contrast, transfection of SMAD4-null pancreatic adenocarcinoma cells PK-1 (b), BxPC-3 (c), and PCI-35 (d) with Flag-tagged full-length SMAD4 (triangles) inhibited significantly the s.c. growth of these cells in NK-depleted SCID mice, as compared to parental cells (squares) or LacZ transfectants (circles, *Po0.05 in all three cases) Figure 3 Histopathological features in tumour tissue. Routine H&E staining of sections from the tumours grown in skinfold chamber revealed the spread of the wild-type PK-1 tumour into the adjacent skin layers (b) and LacZ-transfected PK-1 (c), whereas the SMAD4-transfected PK-1 cells formed tumours that appeared dormant and noninvasive (a, magnification, Â 10). Staining using anti-PECAM-1 (CD31) antibody in PK-1/SMAD4 (d), PK-1/wt (e), and PK-1/LacZ (f) tumour sections showed reduced vascularization in SMAD4-positive tumours. On the other hand, gelatinases staining of s.c. tumour sections from the SMAD4 transfection group (g, MMP-2 and j, MMP-9), and the other groups (h, MMP-2 and k, MMP-9 for wild type, and i, MMP-2 and l, MMP-9 for LacZ, magnification, Â 20) demonstrated a comparatively diminished immunoreactivity for both MMP-2 and MMP-9 (m, *Po0.05, error bars represent standard deviation; dashed bars, PK-1, white bars, PK-1/SMAD4, and black bars, PK-1/LacZ, respectively) Effect of SMAD4 loss in pancreatic cancer cells DG Duda et al of expression in tumour tissue, and that the immunoreactivity was significantly reduced in SMAD4-transfected tumour sections (Figure 3d -m).
Gene and protein expression patterns in pancreatic tumour cells and tissue
RT-PCR, Northern and Western blot and dual luciferase activity analyses assessed the expression levels of SMAD4 and different known regulators of invasion and angiogenesis in wild-type and transfected tumour cells, as well as in human pancreatic tumour tissue samples. By PCR, we confirmed the expression of SMAD4 in tissue from the human tumours grown in mice as late as day 28 (not shown). A decrease in the levels of the EC mitogen VEGF could be observed upon restoration of SMAD4 expression in cell lines (Figure 4a ). However, no significant difference could be detected in basic fibroblast growth factor (bFGF) levels in any of the cell lines used (data not shown). By Western blotting, we found that soluble MMP-2 and MMP-9 levels produced in vitro by pancreatic tumour adenocarcinomas (PK-1, BxPC3 and MiaPaCa2) were downregulated upon SMAD4 restoration/overexpression, but not control infection ( Figure 4 , and not shown). In addition, we investigated at transcriptional level the expression of ETS-1, a marker of tumour invasiveness. Multiplex RT-PCR indicated that although ETS-1 was barely detectable in normal human pancreatic tissue, relatively high levels could be found in samples from human pancreatic carcinoma biopsies, along with decreased SMAD4 levels, which appeared more prominent in locally invasive and metastatic tumour biopsies compared to localized tumours (data not shown). Increased ETS-1 levels were found also in SMAD4-null cell lines (Figure 5b ), and these levels decreased upon SMAD4 restoration (Figure 4 , and not shown). To further confirm the direct inhibition of ETS-1 transcription by SMAD4, we performed a dual luciferase assay. As shown in Figure 5a , we found increased ETS-1 promoter activity in tumour cells, particularly in cells null for SMAD4. Restoration of SMAD4 expression in SMAD4-null cells inhibited significantly the ETS-1 transactivation ability. Similarly, a dramatic decrease in ETS-1 activity was found after transfection of SMAD4 into wild-type SMAD4 cells. Finally, ETS-1 overexpression in MiaPaCa2 cells downregulated SMAD4 expression in a dose-dependent manner, revealing the reciprocal negative regulation between the two signalling factors (Figure 5c and Supplemental Figure 2 ). On the other hand, SMAD5 expression was found ubiquitously, at high levels in all cell and tissue samples ( Figure 5 and not shown).
Discussion
The results reported herein establish a critical role for SMAD4 deletion in pancreatic adenocarcinoma. Specifically, its loss may act as a 'switch' at transcriptional level by mediating the invasion and neovascularization associated with the malignant transformation of the epithelium. Supporting our hypothesis, we found that restoration of SMAD4 significantly delayed tumour growth in vivo. Adenoviral transfer of SMAD4 in SMAD4-null cells restored its expression and function and was correlated with the suppression of angiogenesis and invasion in a xenograft model of human tumour in immunodeficient (SCID) mouse. Although SMAD4 was found to induce G1 cell cycle arrest and apoptosis in SMAD4-null breast and colon cancer cells, it was later suggested that this pathway is not functional in certain pancreatic tumour cells (Dai et al., 1999a, b , 2000) . We report that SMAD4 downregulated the VEGF transcription and the secreted MMP-2 and MMP-9 expression levels consistently along pancreatic adenocarcinoma cell lines. Moreover, we found a significant reduction in the tissue immunoreactivity of MMP-2 (a protease activated in angiogenic vasculature, St Croix et al., 2000) and MMP-9 in samples from mice bearing SMAD4-transfected tumours compared to those from control groups. MMPs have been implicated in primary and metastatic tumour growth and angiogenesis, as well as in tumour invasion and progression (Nelson et al., 2000) . As documented previously, gelatinases control the angiogenesis switch (Itoh et al., 1998; Bergers et al., 2000) . In addition, paracrine interactions may further potentiate invasion and angiogenesis: VEGF is a strong inducer and activator of MMP-2 (Nelson et al., 2000) , while MMP-9 was shown to increase the availability of VEGF to its receptors (Vu et al., 1998) . Thus, autocrine and paracrine interactions may account for the reduced angiogenesis and invasion through direct SMAD4 inhibition of VEGF, MMP-2 and MMP-9 expression in tumour cells. This change in phenotype of the pancreatic cancer cell in vitro upon SMAD4 function restoration was confirmed in vivo using a xenograft tumour model. In recent reports, ETS-1 was established as a novel marker for invasion and poor survival in ovarian carcinoma (Davidson et al., 2001) , and breast cancer relapse with significant correlation to VEGF and PAI-1 levels (Span et al., 2002) . In tumours, ETS-1 plays a critical role because of its effects on matrix reorganization and angiogenesis (reviewed by Taniguchi et al., 1999; Sato et al., 2001) . Of particular interest, our results suggested that the increase in the expression levels of ETS-1 is correlated with SMAD4, and is reduced by restoration of SMAD4 in the tumour cells. To clarify the issue, in a dual luciferase activity assay we found that the promoter activity of ETS-1 is upregulated by SMAD4 deletion, and that the ectopic expression of SMAD4, and not LacZ, significantly downregulates this activity. This result and the observation of increased expression of ETS-1 in tissue from human pancreatic tumours supported the role of SMAD4 in the invasiveness triggered by the malignant transformation of the epithelial cells in pancreatic adenocarcinoma. SMAD4 inhibitory effects on tumour growth by ETS-1 suppression is consistent with the observation that it occurs in the activation phase of angiogenesis, comprising of extracellullar matrix dissolution, invasion, and migration of cells. The reduction in the tissue immunoreactivity of gelatinases plays an important role in the process of shifting toward a malignant phenotype in the pancreatic tissue, as demonstrated previously (Bramhall, 1997) . SMAD4 regulated in vitro MMP-2 and MMP-9 protein expression, and in vivo MMP-2 and MMP-9 levels were found to be reduced in SMAD4-transfected tumour tissue. Gelatinases downregulation by SMAD4 may be the result of an autocrine pathway involving ETS-1 (Behrens et al., 2001; Reisdorff et al., 2002) . It is likely that complex paracrine interactions induce a phenotypical change in endothelial and other stromal cells, translated in the high expression of MMPs found in the tumour tissue. Interestingly, overexpressing ETS-1 results in downregulation of SMAD4 expression, while dominant-negative dose-dependent transcriptional ETS-1 suppression increased SMAD4 in a dose-dependent manner; this points to a bidirectional negative regulation between the two signalling factors in tumour cells. The ETS-1 expression in nulland wild-type SMAD4 tumour cells (MiaPaCa2, Panc-1) was also correlated with the expression of SMAD4. This was further supported by the observation that SMAD4 overexpression in Panc-1 (a wild-type SMAD4 cell, but in which SMAD4 expression is decreased) also delayed their in vivo growth in SCID mouse (not shown).
Our cumulative results offer evidence that SMAD4 significantly suppressed pancreatic tumour growth and invasiveness in vivo. Nevertheless, the loss of expression of SMAD4, the common regulator for TGF-b pathways, may generate interactions among other SMAD molecules. One example is SMAD5, which upon phosphorylation in ECs by activin receptor-like kinase 1 (Oh et al., 2000) , modulates the proper vessel formation. SMAD5 knockout mice are embryonically lethal due to angiogenesis defects consisting of improper matrix and endothelial-mesenchyme interactions (Yang et al., 1999) . SMAD5 molecules could homodimerize or heterodimerize with SMAD4, and heterodimerization is stronger than homodimerization (Jiang et al., 2000) . Importantly, SMAD5 expression was detected at high levels in all pancreatic tumour cells and tissues examined. In addition, in preliminary experiments we found by Western blotting the presence of SMAD5 in nuclear extracts from SMAD4-null cells. In the absence of SMAD4 or upon its inactivation or suppression, accumulation of SMAD5 may promote homodimerization, and upon translocation into the nucleus, may trigger the expression of genes related to angiogenesis and invasion in pancreatic tumours. The existence and the nature of this control are currently under investigation.
In conclusion, the absence, inactivation, or suppression of SMAD4 seems to generate a cascade of events observed in pancreatic tumours, involving high expression of VEGF expression and its availability in the interstitium, as well as gelatinases and ETS-1, concomitant with a reduction in the TSP-1 levels. Changes in the active and/or latent TGF-b in the stroma are likely to modulate these effects, because TGF-b promotes tumour progression at late stages, in contrast to its potent tumour-suppressor properties at early stages of carcinogenesis (Ramachandra et al., 2002) . Upon SMAD4 deletion in pancreatic cancer, the TGF-b activation might promote increased tumorigenesis involving invasion and angiogenesis stimulation, explaining to a certain extent the dichotomous activity of TGFb (Friess et al., 1993; Eskinazi et al., 1998) . The silencing of SMAD4, a late event in pancreatic and colon carcinoma can thus be associated with the 'switching' on of an invasive and angiogenic phenotype, resulting in tumour growth, spreading, and metastasis. Gaining molecular understanding of the complex involvement of the frequent SMAD4 deletion in pancreatic malignancies is crucial, as their poor prognosis emphasizes the need for new diagnostic and therapeutic approaches.
Materials and methods
Mice SCID mice (Fox Chase C. B-17/Icr-SCID Jcl) 6-8 weeks old were used in all experiments and kept in pathogen-confined conditions. Mice bearing dorsal skinfold chamber were housed individually. The study was approved by the Ethics Committee of Tohoku University School of Medicine.
Cell lines and adenoviral gene transfer
The panel of human pancreatic adenocarcinoma cell lines used in our studies consisted of: two wild-type SMAD4 cells -Panc-1 and MiaPaCa2, and PK-1, BxPC3, and PCI-35, cells with homozygous deletion of the SMAD4 gene. Panc-1, MiaPaCa2, and PCI-35, as well as WI38 normal human fibroblasts were maintained in DMEM with high glucose, and PK-1 and BxPC-3 in RPMI 1640 (Gibco, Japan). All cultured media were supplemented with 10% FCS, 100 U/ml penicillin and 0.1 mg/ ml streptomycin, and cells were kept in a humidified 5% CO 2 atmosphere at 371C. Normal pancreatic duct cell line HPDE-6 was a generous gift from Dr M-S Tsao, University of Toronto, and was maintained as described (Furukawa et al., 1996) . All cells were routinely monitored for mycoplasma, mouse hepatitis, Sendai and pneumonia viruses. Gene transfer in tumour cells was carried out using adenoviral vectors encoding for the Flag-tagged SMAD4 gene or the LacZ gene at varying MOI from 10 to 200 for 36 h. An adenovirus encoding the fulllength human ETS-1 gene and a mutant dominant negative construct were kindly provided by Dr Y Sato, Tohoku University. The gene transfer efficiency was assessed using b-galactosidase staining after LacZ transfer, as described elsewhere (Jiao et al., 1993) .
Effect of SMAD4 on in vitro tumour growth
In order to evaluate the cytotoxic effect of SMAD4 expression on the tumour cells; 1000 tumour cells were plated in a 96-well plate and infected for 36 h with an adenoviral vector encoding SMAD4 using increasing MOI from 0 to 200. At 5 days after infection, 10 ml of the sterile tetrazolium salt, MTT (Sigma Chemical Co., St Louis, MO, USA) was added to the wells and incubated for 4 h at 371C. Finally, 100 ml of 10% SDS was added and, after incubation at 371C overnight, the plate was measured at 490 nm. The reduction in optical density induced by adenoviral transfection was used as a measure of viability, normalized to cells incubated in the absence of transfection (MOI 0), which were considered 100% viable.
In vivo growth of human tumour xenografts
One million tumour cells, PK-1, BxPC-3, and PCI-35 were inoculated subcutaneously. Mice were divided into three experimental groups receiving a wild-type, LacZ-or SMAD4-transfected tumour xenotransplant, respectively (n ¼ 4-6). Tumour volume was estimated by the formula:
4 (V is the tumour volume, D is the largest dimension, and d is the smallest dimension) after biweekly measurements. NK cell depletion in SCID mice was obtained by biweekly administration of antiasialo GM-1 antibody (Wako, Japan) via the tail vein.
Intravital microscopy
In a modified dorsal transparent chamber and in vivo microscopy system, described elsewhere (Duda et al., 2000) , the mice received a 2 ml cell implant (2 Â 10 5 cells) of SMAD4-transfected PK-1 cells, wild-type PK-1, or LacZ-transfected PK-1 cells. Tumour angiogenesis was observed for 3 weeks after tumour cell pellet implantation. Images were captured by a CCD camera (TEC-470 Optronics Co., Chelmsford, MA, USA), attached to a microscope (Nikon, Japan), and recorded on a Super VHS video recorder (Victor, Japan). Finally, they were analysed and prepared off-line using Avid VideoShop 3.0.2 (Avid Technology Inc., Tewksbury, MA, USA) and Adobe Photoshop 5.0.2 (Adobe Systems Inc., San Jose, CA, USA) software.
Tumour histopathology
Tumour samples were fixed in 10% formalin and then embedded in paraffin. Standard haematoxylin and eosin staining (H&E) was performed on 3-5 mm sections. Staining of ECs was performed as using rat anti-mouse PECAM-1 (CD31) antibody (BD Pharmingen, San Diego, CA, USA), as described (Vlaykova et al., 1997) . The immunostaining of gelatinases (MMP-2 and MMP-9) was performed as previously described (Sun et al., 1999; Thant et al., 1999) , using goat antimouse antibodies (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), which are reactive also for human gelatinases. Quantification of the staining results was made by determining the percentage of stained cells in 10 random high-power fields.
Electrophoretic mobility shift assay DNA-binding assays for SMAD4 protein were performed using 10 mg of nuclear extract, as described (Iwasaka et al., 1996) . (10 ng) of 32 P-labeled double-stranded SBE oligonucleotides from the p21waf1 gene promoter region were used as a Effect of SMAD4 loss in pancreatic cancer cells DG Duda et al probe.
Competition assays were performed with a 100-fold excess of unlabelled wild-type (WT-SBE) or mutant SBE (MT-SBE) oligonucleotides (Peng et al., 2002) . For supershift assays, 2 ml of the SMAD4 antibodies were incubated with nuclear extracts for 60 min at room temperature before the addition of radiolabelled probe. The reactions were analysed on a native 4% polyacrylamide gel and exposed to an imaging plate, which was analysed with a BAS 2000 image analyzer (Fuji, Tokyo, Japan).
Semiquantitative RT-PCR and northern blot analyses
Total cellular RNA was extracted from tumour cells, tumour tissues from mice, as well as from human primary tumour or normal tissue samples using RNeasy Mini Kit (Qiagen, Japan). Aliquots of 10 ml were reverse transcribed and 1 mg of the resultant cDNA was amplified in duplex or triplex PCR reactions using primers with the nucleotide sequences, annealing temperatures and number of amplification cycles, as shown in Table 1 . Expression of hMSH2 was monitored as internal control. Aliquots from the amplification reactions were electrophoresed on 2% agarose gels and autoradiographed. For Northern blotting, 10 mg of the total RNA extracted was subjected to electrophoresis on a 1% agarose gel containing 5% formalin, and then transferred to a Hybond N þ membrane (Amersham, Sweden). Probes for ETS-1 and VEGF were obtained from the RT-PCR products. Direct sequencing using ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit and a 310 DNA sequencer (Applied Biosystems, Foster City, CA, USA) confirmed the sequences of these fragments. Using a human b-actin probe as control, the membrane was hybridized in ExpressHyb solution (Clonetech, Palo Alto, CA, USA) with 32 P-radiolabelled probes for 16 h at 681C. Then the membrane was washed sequentially with 2 Â SSC/0.05% SDS at room temperature and with 0.1 Â SSC/ 0.1% SDS at 601C. Digital autoradiography and the quantification of the results were carried out using the BAS 1500 and Image Gauge 3.3 (FUJIFILM, Japan) software.
Dual luciferase assay
The assay was performed as described . Briefly, the reporter construct was generated by inserting five head-to-tail ligated copies of the oligonucleotide 5 0 -TCGAG-CAGGAAGTTTCG-3 0 , which contained the PEA3 Ets binding site from the polyoma virus enhancer into pGL3-basic vector, which contained firefly luciferase cDNA (Promega, Madison, WI, USA). The cells were transfected with Ad/ETS-1, Ad/SMAD4, or Ad/LacZ for 36 h at an MOI of 50, then transferred in 12-well plates. When cells were 50-70% confluent, 10 mg of promoter-reporter plasmid DNA and 1 mg of internal control pRL-TK (Promega, Madison, WI, USA) per well were transfected into the cells by using LipofectAMINE 2000 (Life Technologies, Inc.) according to the manufacturer's recommendations. pRL-CMV was used to normalize the transfection efficiency. An empty vector, pcDNA3 (Invitrogen, Carlsbad, CA, USA), was used to keep total plasmid DNA constant. After 36 h, firefly (FLS) and renilla luciferase (RLS) gene activities in extracts from triplicate samples were sequentially measured by using a Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Measurements were performed automatically in a Luminescencer (Lumat LB 9507, Berthold, Germany) and results were expressed as FLS/RLS units.
Western blot analysis
Western blotting was performed using 20 mg of total tumour cell lysate or culture supernatant, as previously described (Kondo et al., 1999; Attiga et al., 2000) . Antibodies used were: polyclonal rabbit anti-human ETS-1, monoclonal mouse antihuman SMAD4, and goat anti-human MMP-2 and MMP-9 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), monoclonal mouse anti-Flag and anti-human b-actin (Sigma, St Louis, MO, USA). The relative intensity of signals was analysed using the Luminescent Image Analyzer LAS-1000 Plus and Image software Gauge 3.3 (FUJI Photo Film, Co. Ltd., Minamiashigara, Japan).
Statistical analysis
All experiments were performed in duplicate or triplicate. A two-tailed Student's t-test was used for statistical analysis of comparative data. Values of Po0.05 were considered significant. 
